Sirilumab ( SAPHYR trial) in PMR, By Dr.Robert Spiera #RNL2023 ⁦@RheumNow⁩ It also improved patient reported outcomes. Great news👌 https://t.co/NDxhIwvACq

Preterm deliveries in PsA pregnancies were more pronounced with 1- first pregnancy. 2- Discontinuation of biologic prior to pregnancy. By Dr.Chambers #RNL2023 ⁦@RheumNow⁩ https://t.co/CxZh0ak4l0

Neonatal outcomes: Small for gestational age more common with an Adjusted OR off 2.42 and statistically significant. By Dr.Chambers #RNL2023 ⁦@RheumNow⁩ https://t.co/NFMAEROEEM

Pregnancy and #PsA Risk of preterm delivery if ➡️first pregnancy ➡️biologic stopped pre-pregnancy Dr Chambers at #RNL2023 https://t.co/yImZRwMuI8

Why JAKinibs in PsA ?! By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Also inflammatory bowel disease and most recently Upadacitinib for crohns disease. https://t.co/loUgJNUsKT

Jaks are every where in Psoriatic disease domains, By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Good news, especially with Updacitinib recently and Crohn’s disease ( full package). https://t.co/nlBWJhzpLp

What influences global scores to patients is different from physicians by Laura Coates #RNL2023 ⁦@RheumNow⁩ https://t.co/bTKozGeON6

Patients definition of remission in PsA, by Laura Coates #RNL2023 ⁦@RheumNow⁩ https://t.co/kphM14SH0E

#RNL2023 AGATA trial showed benefit of Abatecept in GCA - 48 to 31% disease free survival Robert Spiera @RheumNow https://t.co/pPzbdTTvEi

#RNL2023 Rob Spiera: I often use aspirin a day, especially if cranial complications and no contra-indications" No prospective studies, 2 large retrospective studies suggesting benefit @RheumNow https://t.co/OedVG03yN3

#RNL2023 Resources for pregnancy and lactation for patients on various #medications and #chronic #diseases. Have a look. Pregnant 🫃 #baby and #breast #feeding. https://t.co/A8zmBUAylG

Is there role for MTX in GCA Favorable results in a meta-analysis with NNT 11 to prevent 1 cranial relapse BUT: limitations of meta-analysis, short follow-up, dose response not evaluated Robert Spiera at #RNL2023 @RheumNow https://t.co/sHx2ceVmAi

DMARDs/TNF for PMR: MTX- initial benefit, but no 5 year steroid sparing effect Infliximab - no benefit Lef - some benefit in case series Robert Spiera #RNL2023 @RheumNow https://t.co/cmwGEWHQEO

IL-6 for PMR SPARE and SEMAPORE (Toci), SAPHYR (Sari) 2/2023: FDA approves sarilumab for PMR for inadequate response to corticosteroids or unable to taper off Robert Spiera @RheumNow #RNL2023 https://t.co/quOWjJjgB3

Dr. Robert Spiera on Recent IL-6i in PMR treatment: SPARE and SEMAPHORE study - Tocilizumab SAPHYR - Sarilumab (now FDA approved for PMR tx) @RheumNow #RNL2023 https://t.co/gofe54wSjo